New hope for advanced cancer: AK150 drug trial launches
NCT ID NCT07566247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called AK150 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan People's Hospital
Dongguan, Guangdong, 523000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral drug elraglusib aims to tame advanced solid tumors
- Engineered virus targets Hard-to-Treat cancers from the inside
- New drug combo targets Hard-to-Treat cancers
- Engineered herpes virus takes aim at Hard-to-Treat cancers
- Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
- New drug combo takes on advanced cancers